Cefotaxime (HR-756) in urinary tract infections.
A total of 30 hospitalized patients with upper and lower urinary tract infections were treated with cefotaxime (HR-756) by intramuscular or intravenous route. All patients had a monomicrobial infection, and the major part of bacterial isolates were gram-negative bacilli (83%) while gram-positive cocci accounted only for 17%. In 83% of the cefotaxime-treated patients both the bacteria and symptoms were eliminated at the 2nd week of follow-up, while failure or relapse occurred in 17% of the patients. No reinfections were recorded. Cefotaxime was a safe and well-tolerated drug and can be considered as an effective antibiotic in the therapy of urinary tract infections caused by "difficult' gram-negative bacilli.
D000328:Adult; D000368:Aged; D002439:Cefotaxime / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D005260:Female; D006801:Humans; D007263:Infusions, Parenteral; D007273:Injections, Intramuscular; D008297:Male; D008875:Middle Aged; D014552:Urinary Tract Infections / Q000188:drug therapy* / Q000382:microbiology
D002439:Cefotaxime